Mark J. Millan

Mark J. Millan publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Mark J. Millan sits on this spectrum.

Mark J. Millan D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Mark J. Millan sits on this spectrum.

Best Publications

• Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.

  Mark J. Millan

  746
  Citations

• Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

  Mark J. Millan;Lisa Maiofiss;Didier Cussac;Valérie Audinot

  628
  Citations

• Altering the course of schizophrenia: progress and perspectives

  Mark J. Millan;Annie Andrieux;George Bartzokis;Kristin Cadenhead

  599
  Citations

• Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors

  Mark J. Millan

  434
  Citations

• Antinociceptive effects of mu- and kappa-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism.

  Christoph Stein;M.J. Millan;M.J. Millan;A. Yassouridis;A. Yassouridis;A. Herz;A. Herz

  287
  Citations

• Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study

  Adrian Newman-Tancredi;Samantha Gavaudan;Caroline Conte;Christine Chaput

  283
  Citations

• Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.

  Mark J. Millan;Adrian Newman‐Tancredi;Valérie Audinot;Didier Cussac

  266
  Citations

• The endocrinology of the opioids.

  Mark J. Millan;Albert Herz

  244
  Citations

• Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.

  Adrian Newman-Tancredi;Didier Cussac;Valérie Audinot;Jean-Paul Nicolas

  237
  Citations

• Stress-induced release of brain and pituitary beta-endorphin: major role of endorphins in generation of hyperthermia, not analgesia.

  M.J. Millan;R. Przewlock;M. Jerlicz;Ch. Gramsch

  222
  Citations

• Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex

  David J G Watson;Florence Loiseau;Manuela Ingallinesi;Mark J Millan

  203
  Citations

• Potentiation of the Fluoxetine-Induced Increase in Dialysate Levels of Serotonin (5-HT) in the Frontal Cortex of Freely Moving Rats by Combined Blockade of 5-HT1A and 5-HT1B Receptors with WAY 100,635 and GR 127,935

  A Gobert;J M Rivet;L Cistarelli;M J Millan

  190
  Citations

• Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone

  Rudy Schreiber;Mauricette Brocco;Mark J. Millan

  189
  Citations

• S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.

  Mark J. Millan;Alain Gobert;Adrian Newman-Tancredi;Françoise Lejeune

  176
  Citations

• Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.

  A. Newman-Tancredi;C. Chaput;L. Verriele;M.J. Millan

  169
  Citations

• S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

  Millan Mj;Dekeyne A;Papp M;La Rochelle Cd

  165
  Citations

• Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry

  Philippe De Deurwaerdère;Giuseppe Di Giovanni;Giuseppe Di Giovanni;Mark J. Millan

  145
  Citations

• α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats

  A Gobert;J M Rivet;L Cistarelli;C Melon

  145
  Citations

• Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.

  Françoise Lejeune;Mark J. Millan

  143
  Citations

• (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.

  Unknown

  120
  Citations